ClinicalTrials.gov record
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
ClinicalTrials.gov ID: NCT00031681
Public ClinicalTrials.gov record NCT00031681. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
ClinicalTrials.gov public records Last synced May 20, 2026, 11:47 AM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II)
Study identification
- NCT ID
- NCT00031681
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 41 participants
Conditions and interventions
Conditions
- Advanced Adult Primary Liver Cancer
- Carcinoma of the Appendix
- Estrogen Receptor-negative Breast Cancer
- Extensive Stage Small Cell Lung Cancer
- Gastrointestinal Stromal Tumor
- HER2-negative Breast Cancer
- Metastatic Gastrointestinal Carcinoid Tumor
- Ovarian Sarcoma
- Ovarian Stromal Cancer
- Progesterone Receptor-negative Breast Cancer
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Recurrent Adult Primary Liver Cancer
- Recurrent Anal Cancer
- Recurrent Basal Cell Carcinoma of the Lip
- Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor
- Recurrent Breast Cancer
- Recurrent Cervical Cancer
- Recurrent Colon Cancer
- Recurrent Endometrial Carcinoma
- Recurrent Esophageal Cancer
- Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Recurrent Extrahepatic Bile Duct Cancer
- Recurrent Gallbladder Cancer
- Recurrent Gastric Cancer
- Recurrent Gastrointestinal Carcinoid Tumor
- Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Recurrent Lymphoepithelioma of the Nasopharynx
- Recurrent Lymphoepithelioma of the Oropharynx
- Recurrent Metastatic Squamous Neck Cancer With Occult Primary
- Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
- Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
- Recurrent Non-small Cell Lung Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Ovarian Germ Cell Tumor
- Recurrent Pancreatic Cancer
- Recurrent Prostate Cancer
- Recurrent Rectal Cancer
- Recurrent Salivary Gland Cancer
- Recurrent Small Cell Lung Cancer
- Recurrent Small Intestine Cancer
- Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Recurrent Squamous Cell Carcinoma of the Larynx
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Recurrent Squamous Cell Carcinoma of the Nasopharynx
- Recurrent Squamous Cell Carcinoma of the Oropharynx
- Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Recurrent Verrucous Carcinoma of the Larynx
- Recurrent Verrucous Carcinoma of the Oral Cavity
- Small Intestine Adenocarcinoma
- Small Intestine Leiomyosarcoma
- Small Intestine Lymphoma
- Stage IV Adenoid Cystic Carcinoma of the Oral Cavity
- Stage IV Anal Cancer
- Stage IV Basal Cell Carcinoma of the Lip
- Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor
- Stage IV Breast Cancer
- Stage IV Colon Cancer
- Stage IV Endometrial Carcinoma
- Stage IV Esophageal Cancer
- Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Stage IV Gastric Cancer
- Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Stage IV Lymphoepithelioma of the Nasopharynx
- Stage IV Lymphoepithelioma of the Oropharynx
- Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
- Stage IV Mucoepidermoid Carcinoma of the Oral Cavity
- Stage IV Non-small Cell Lung Cancer
- Stage IV Ovarian Epithelial Cancer
- Stage IV Ovarian Germ Cell Tumor
- Stage IV Pancreatic Cancer
- Stage IV Prostate Cancer
- Stage IV Rectal Cancer
- Stage IV Salivary Gland Cancer
- Stage IV Squamous Cell Carcinoma of the Hypopharynx
- Stage IV Squamous Cell Carcinoma of the Larynx
- Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IV Squamous Cell Carcinoma of the Nasopharynx
- Stage IV Squamous Cell Carcinoma of the Oropharynx
- Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Stage IV Verrucous Carcinoma of the Larynx
- Stage IV Verrucous Carcinoma of the Oral Cavity
- Stage IVA Cervical Cancer
- Stage IVB Cervical Cancer
- Triple-negative Breast Cancer
- Unresectable Extrahepatic Bile Duct Cancer
- Unresectable Gallbladder Cancer
- Unspecified Adult Solid Tumor, Protocol Specific
- Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
- 7-hydroxystaurosporine Drug
- diagnostic laboratory biomarker analysis Other
- irinotecan hydrochloride Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2001
- Primary completion
- Dec 31, 2010
- Completion
- Not listed
- Last update posted
- Sep 29, 2013
Started 2001
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Virginia | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00031681, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2013 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00031681 live on ClinicalTrials.gov.